JY
EFTR

Jeff Yass’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Jeff Yass’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,944
Closed -$22.8K – 13681
2023
Q4 		$22.8K Buy
+1,944
New +$26.1K ﹤0.01% 11949

Other funds holding EFTR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jeff Yass's EFTR Position: Q4 2023 in Review

Jeff Yass sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2023, closing a stake of 1,976 shares — an estimated $26.5K sold.

Jeff Yass first reported a position in EFTR in Q4 2022 and held it in 4 quarters. The position peaked at $39.1K in Q2 2023. 25 funds tracked by Wall St. Rank hold EFTR as of Q4 2023.

  • Jeff Yass reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Jeff Yass sold 1,976 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $26.5K.
  • Jeff Yass first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Jeff Yass's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $39.1K in Q2 2023.
  • 25 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.